Takeda San Diego re-acquires DPP4 rights
Takeda San Diego (formerly Syrrx, before its acquisition by Takeda Pharmaceutical in February 2005) has re-acquired worldwide development and marketing rights to the dipeptidyl peptidase IV (DPP4) inhibitors that it formerly shared with PPD under a 2003 agreement.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.